Linked Life Data

10393815

Source:http://linkedlifedata.com/resource/pubmed/id/10393815

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10393815rdf:typepubmed:Citationlld:pubmed
pubmed-article:10393815lifeskim:mentionsumls-concept:C0035820lld:lifeskim
pubmed-article:10393815lifeskim:mentionsumls-concept:C0042071lld:lifeskim
pubmed-article:10393815lifeskim:mentionsumls-concept:C0225336lld:lifeskim
pubmed-article:10393815lifeskim:mentionsumls-concept:C0521119lld:lifeskim
pubmed-article:10393815lifeskim:mentionsumls-concept:C0302600lld:lifeskim
pubmed-article:10393815lifeskim:mentionsumls-concept:C0380603lld:lifeskim
pubmed-article:10393815lifeskim:mentionsumls-concept:C0041904lld:lifeskim
pubmed-article:10393815lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:10393815pubmed:dateCreated1999-10-14lld:pubmed
pubmed-article:10393815pubmed:abstractTextDownstream signaling triggered by the binding of fibroblast growth factor-2 (FGF2) to its tyrosine-kinase receptors involves the activation of mitogen-activated protein kinase kinase (MEK) with consequent phosphorylation of extracellular signal-regulated kinases (ERKs). Here we demonstrate that FGF2 induces ERK1/2 activation in bovine aortic endothelial (BAE) cells and that the continuous presence of the growth factor is required for sustained ERK1/2 phosphorylation. This is prevented by the MEK inhibitors PD 098059 and U0126, which also inhibit FGF2-mediated upregulation of urokinase-type plasminogen activator (uPA) and in vitro formation of capillary-like structures in three-dimensional type I collagen gel. Various FGF2 mutants originated by deletion or substitution of basic amino acid residues in the amino terminus or in the carboxyl terminus of FGF2 retained the capacity to induce a long-lasting activation of ERK1/2 in BAE cells. Among them, K128Q/R129Q-FGF2 was also able to stimulate uPA production and morphogenesis whereas R129Q/K134Q-FGF2 caused uPA upregulation only. In contrast, K27, 30Q/R31Q-FGF2, K128Q/K138Q-FGF2 and R118,129Q/K119,128Q-FGF2 exerted a significant uPA-inducing and morphogenic activity in an ERK1/2-dependent manner only in the presence of heparin. Furthermore, no uPA upregulation and morphogenesis was observed in BAE cells treated with the deletion mutant (delta)27-32-FGF2 even in the presence of soluble heparin. Thus, mutational analysis of FGF2 dissociates the capacity of the growth factor to induce a persistent activation of ERK1/2 from its ability to stimulate uPA upregulation and/or in vitro angiogenesis. In conclusion, the data indicate that ERK1/2 phosphorylation is a key step in the signal transduction pathway switched on by FGF2 in endothelial cells. Nevertheless, a sustained ERK1/2 activation is not sufficient to trigger uPA upregulation and morphogenesis. FGF2 mutants may represent useful tools to dissect the signal transduction pathway(s) mediating the complex response elicited by an angiogenic stimulus in endothelial cells.lld:pubmed
pubmed-article:10393815pubmed:languageenglld:pubmed
pubmed-article:10393815pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10393815pubmed:citationSubsetIMlld:pubmed
pubmed-article:10393815pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10393815pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10393815pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10393815pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10393815pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10393815pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10393815pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10393815pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10393815pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10393815pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10393815pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10393815pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10393815pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10393815pubmed:statusMEDLINElld:pubmed
pubmed-article:10393815pubmed:monthAuglld:pubmed
pubmed-article:10393815pubmed:issn0021-9533lld:pubmed
pubmed-article:10393815pubmed:authorpubmed-author:GiulianiRRlld:pubmed
pubmed-article:10393815pubmed:authorpubmed-author:PrestaMMlld:pubmed
pubmed-article:10393815pubmed:authorpubmed-author:BastakiMMlld:pubmed
pubmed-article:10393815pubmed:authorpubmed-author:ColtriniDDlld:pubmed
pubmed-article:10393815pubmed:issnTypePrintlld:pubmed
pubmed-article:10393815pubmed:volume112 ( Pt 15)lld:pubmed
pubmed-article:10393815pubmed:ownerNLMlld:pubmed
pubmed-article:10393815pubmed:authorsCompleteYlld:pubmed
pubmed-article:10393815pubmed:pagination2597-606lld:pubmed
pubmed-article:10393815pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:10393815pubmed:meshHeadingpubmed-meshheading:10393815...lld:pubmed
pubmed-article:10393815pubmed:meshHeadingpubmed-meshheading:10393815...lld:pubmed
pubmed-article:10393815pubmed:meshHeadingpubmed-meshheading:10393815...lld:pubmed
pubmed-article:10393815pubmed:meshHeadingpubmed-meshheading:10393815...lld:pubmed
pubmed-article:10393815pubmed:meshHeadingpubmed-meshheading:10393815...lld:pubmed
pubmed-article:10393815pubmed:meshHeadingpubmed-meshheading:10393815...lld:pubmed
pubmed-article:10393815pubmed:meshHeadingpubmed-meshheading:10393815...lld:pubmed
pubmed-article:10393815pubmed:meshHeadingpubmed-meshheading:10393815...lld:pubmed
pubmed-article:10393815pubmed:meshHeadingpubmed-meshheading:10393815...lld:pubmed
pubmed-article:10393815pubmed:meshHeadingpubmed-meshheading:10393815...lld:pubmed
pubmed-article:10393815pubmed:meshHeadingpubmed-meshheading:10393815...lld:pubmed
pubmed-article:10393815pubmed:meshHeadingpubmed-meshheading:10393815...lld:pubmed
pubmed-article:10393815pubmed:meshHeadingpubmed-meshheading:10393815...lld:pubmed
pubmed-article:10393815pubmed:meshHeadingpubmed-meshheading:10393815...lld:pubmed
pubmed-article:10393815pubmed:meshHeadingpubmed-meshheading:10393815...lld:pubmed
pubmed-article:10393815pubmed:meshHeadingpubmed-meshheading:10393815...lld:pubmed
pubmed-article:10393815pubmed:meshHeadingpubmed-meshheading:10393815...lld:pubmed
pubmed-article:10393815pubmed:meshHeadingpubmed-meshheading:10393815...lld:pubmed
pubmed-article:10393815pubmed:meshHeadingpubmed-meshheading:10393815...lld:pubmed
pubmed-article:10393815pubmed:meshHeadingpubmed-meshheading:10393815...lld:pubmed
pubmed-article:10393815pubmed:meshHeadingpubmed-meshheading:10393815...lld:pubmed
pubmed-article:10393815pubmed:meshHeadingpubmed-meshheading:10393815...lld:pubmed
pubmed-article:10393815pubmed:year1999lld:pubmed
pubmed-article:10393815pubmed:articleTitleRole of endothelial cell extracellular signal-regulated kinase1/2 in urokinase-type plasminogen activator upregulation and in vitro angiogenesis by fibroblast growth factor-2.lld:pubmed
pubmed-article:10393815pubmed:affiliationUnit of General Pathology and Immunology, Department of Biomedical Sciences and Biotechnology, University of Brescia, Italy.lld:pubmed
pubmed-article:10393815pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10393815pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10393815lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10393815lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10393815lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10393815lld:pubmed